To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Improving the economics o… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Improving the economics of NASH/NAFLD treatment through the use of systems biology

Journal article
Authors J. Bosley
C. Boren
S. Lee
Morten Grötli
J. Nielsen
M. Uhlen
Jan Borén
A. Mardinoglu
Published in Drug Discovery Today
Volume 22
Issue 10
Pages 1532-1538
ISSN 1359-6446
Publication year 2017
Published at Department of Chemistry and Molecular Biology
Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 1532-1538
Language en
Links 10.1016/j.drudis.2017.07.005
Keywords fatty liver-disease, plasma mannose levels, cardiovascular-disease, adipose-tissue, human proteome, genome-scale, metabolism, nafld, medicine, reveals, Pharmacology & Pharmacy
Subject categories Pharmacology

Abstract

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD). We surveyed NASH therapies currently in development, and found a significant variety of targets and approaches. Evaluation and clinical testing of these targets is an expensive and time-consuming process. Systems biology approaches could enable the quantitative evaluation of the likely efficacy and safety of different targets. This motivated our review of recent systems biology studies that focus on the identification of targets and development of effective treatments for NASH. We discuss the potential broader use of genome-scale metabolic models and integrated networks in the validation of drug targets, which could facilitate more productive and efficient drug development decisions for the treatment of NASH.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?